Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. May 21, 2025; 31(19): 101913
Published online May 21, 2025. doi: 10.3748/wjg.v31.i19.101913
Table 1 Patient characteristics at baseline
Characteristics
Sequential group, overall
Sequential group, side by side
Sequential group, stent in stent
Simultaneous group
P value
Number of patients73353862
Male41 (56)21 (51)20 (49)35 (56)0.82
Age, years, median717171680.59
Tumor type0.32
    Cholangiocarcinoma34 (47)19 (54)15 (39)38 (61)
    Hilar metastasis34 (47)14 (40)20 (53)21 (34)
    Hepatocarcinoma5 (6)2 (6)3 (8)3 (5)
Bismuth and Corlette classification0.053
    II1 (1)0 (0)1 (2)8 (12)
    IIIa17 (23)11 (31)6 (16)9 (15)
    IIIb5 (7)2 (6)3 (8)9 (15)
    IV50 (69)22 (63)28 (74)36 (58)
Bilirubin rate, day 0, μmol/L, median (IQR)224 (158-340)238 (162-342)220 (150-338)225 (132-334)0.80
Postoperative chemotherapy25 (36)14 (42)11 (30)31 (53)0.095
Survival time, days, median (IQR)61 (39-78)69 (43-128)43 (27-65)67 (56-105)0.24